Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Anna Agrusti, Clémence David, Sylvain Breton, Isabelle Melki, Pierre Quartier, Cécile Dumaine, Héloïse Reumaux, A.-L. Jurquet, Benjamin Fournier, Luís Seabra, Gillian Rice, Brigitte Bader‐Meunier, Marie‐Louise Frémond
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001
2004
Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor
10.1002/art.22709 · 2007
Role of IFN-α in Rheumatoid Arthritis
10.1007/s11926-023-01125-6 · 2024
The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease
10.1016/s2665-9913(21)00254-x · 2022
The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy
10.1016/j.jaci.2017.08.026 · 2018
Heterogeneity of the type I interferon signature in rheumatoid arthritis: a potential limitation for its use as a clinical biomarker
10.3389/fimmu.2017.02007 · 2018
Identification and validation of interferon-driven gene signature as a predictor of response to methotrexate in juvenile idiopathic arthritis
10.1016/j.ard.2025.03.007 · 2025
Genetic Association of juvenile idiopathic arthritis with adult rheumatic disease
10.1001/jamanetworkopen.2024.51341 · 2024
Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts
10.1016/s2665-9913(19)30142-0 · 2020
Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype
10.1186/s12969-020-00425-w · 2020
A toddler with an unusually severe polyarticular arthritis and a lung involvement: a case report
10.1186/s12887-022-03716-1 · 2022
Rheumatoid factor positive polyarticular juvenile idiopathic arthritis associated with a novel COPA mutation
10.1093/rheumatology/keaa763 · 2021
How common is remission in rheumatoid factor-positive juvenile idiopathic arthritis patients? The multicenter Pediatric Rheumatology Academy (PeRA) research group experience
10.1186/s12969-023-00860-5 · 2023
American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis
10.1002/acr.20497 · 2011
Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling
10.1084/jem.20200600 · 2020
CADD: predicting the deleteriousness of variants throughout the human genome
10.1093/nar/gky1016 · 2019
WW domain containing E3 ubiquitin protein ligase 1 (WWP1) negatively regulates TLR4-mediated TNF-α and IL-6 production by proteasomal degradation of TNF receptor associated factor 6 (TRAF6)
10.1371/journal.pone.0067633 · 2013
Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management
10.1183/16000617.0011-2021 · 2021
Endothelial cell expression of a STING gain-of-function mutation initiates pulmonary lymphocytic infiltration
10.1016/j.celrep.2024.114114 · 2024
Case report: Novel UNC93B1 variant causes rheumatoid arthritis and interstitial pneumonia
10.3389/fimmu.2025.1671984 · 2025
Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) among 21 patients
10.1016/j.jaip.2020.11.007 · 2021
Lung Inflammation in STING-Associated Vasculopathy with Onset in Infancy (SAVI)
10.3390/cells11030318 · 2022
Rheumatoid arthritis-associated interstitial pneumonia refractory to initial therapy: successful control through combined anti-inflammatory, antifibrotic and JAK-STAT-targeted treatment
10.1002/rcr2.70378 · 2025
The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort
10.1136/annrheumdis-2014-205372 · 201
Common diseases in clinical cohorts - not always what they seem
10.1056/nejmoa2405459 · 2025
Baricitinib in juvenile idiopathic arthritis: an: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial
10.1016/s0140-6736(23)00921-2 · 2023
No additional external references are available.